

# Global Severe Acute Respiratory Syndrome Treatment Market Growth 2023-2029

https://marketpublishers.com/r/GBA03A64FBC8EN.html

Date: March 2023

Pages: 109

Price: US\$ 3,660.00 (Single User License)

ID: GBA03A64FBC8EN

# **Abstracts**

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Severe Acute Respiratory Syndrome Treatment market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Severe Acute Respiratory Syndrome Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Severe Acute Respiratory Syndrome Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Severe Acute Respiratory Syndrome Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Severe Acute Respiratory Syndrome Treatment players cover AstraZeneca plc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GSK, Merck, Pfizer, Regeneron Pharmaceuticals, Inc. and Swedish Orphan Biovitrum, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Severe Acute Respiratory Syndrome (SARS) is a viral respiratory illness caused by the SARS coronavirus. There is no specific treatment for SARS; however, treatment



typically involves supportive care to relieve symptoms and help the body fight the virus. This could include oxygen therapy, pain & fever management, and breathing support.

LPI (LP Information)' newest research report, the "Severe Acute Respiratory Syndrome Treatment Industry Forecast" looks at past sales and reviews total world Severe Acute Respiratory Syndrome Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Severe Acute Respiratory Syndrome Treatment sales for 2023 through 2029. With Severe Acute Respiratory Syndrome Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Severe Acute Respiratory Syndrome Treatment industry.

This Insight Report provides a comprehensive analysis of the global Severe Acute Respiratory Syndrome Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Severe Acute Respiratory Syndrome Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Severe Acute Respiratory Syndrome Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Severe Acute Respiratory Syndrome Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Severe Acute Respiratory Syndrome Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Severe Acute Respiratory Syndrome Treatment market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:


Segmentation by type

**Antibiotics** 









The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

AstraZeneca plc

Eli Lilly and Company



F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GSK
Merck
Pfizer
Regeneron Pharmaceuticals, Inc.
Swedish Orphan Biovitrum
CN Bio
AbbVie
Key Questions Addressed in this Report
What is the 10-year outlook for the global Severe Acute Respiratory Syndrome Treatment market?
What factors are driving Severe Acute Respiratory Syndrome Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Severe Acute Respiratory Syndrome Treatment market opportunities vary by end market size?
How does Severe Acute Respiratory Syndrome Treatment break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?



# **Contents**

#### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### **2 EXECUTIVE SUMMARY**

- 2.1 World Market Overview
  - 2.1.1 Global Severe Acute Respiratory Syndrome Treatment Annual Sales 2018-2029
  - 2.1.2 World Current & Future Analysis for Severe Acute Respiratory Syndrome

Treatment by Geographic Region, 2018, 2022 & 2029

- 2.1.3 World Current & Future Analysis for Severe Acute Respiratory Syndrome Treatment by Country/Region, 2018, 2022 & 2029
- 2.2 Severe Acute Respiratory Syndrome Treatment Segment by Type
  - 2.2.1 Antibiotics
  - 2.2.2 Antivirals
  - 2.2.3 Corticosteroids
  - 2.2.4 Monoclonal Antibodies
  - 2.2.5 Others
- 2.3 Severe Acute Respiratory Syndrome Treatment Sales by Type
- 2.3.1 Global Severe Acute Respiratory Syndrome Treatment Sales Market Share by Type (2018-2023)
- 2.3.2 Global Severe Acute Respiratory Syndrome Treatment Revenue and Market Share by Type (2018-2023)
- 2.3.3 Global Severe Acute Respiratory Syndrome Treatment Sale Price by Type (2018-2023)
- 2.4 Severe Acute Respiratory Syndrome Treatment Segment by Application
  - 2.4.1 Hospital
  - 2.4.2 Retail pharmacies
  - 2.4.3 Others
- 2.5 Severe Acute Respiratory Syndrome Treatment Sales by Application



- 2.5.1 Global Severe Acute Respiratory Syndrome Treatment Sale Market Share by Application (2018-2023)
- 2.5.2 Global Severe Acute Respiratory Syndrome Treatment Revenue and Market Share by Application (2018-2023)
- 2.5.3 Global Severe Acute Respiratory Syndrome Treatment Sale Price by Application (2018-2023)

# 3 GLOBAL SEVERE ACUTE RESPIRATORY SYNDROME TREATMENT BY COMPANY

- 3.1 Global Severe Acute Respiratory Syndrome Treatment Breakdown Data by Company
- 3.1.1 Global Severe Acute Respiratory Syndrome Treatment Annual Sales by Company (2018-2023)
- 3.1.2 Global Severe Acute Respiratory Syndrome Treatment Sales Market Share by Company (2018-2023)
- 3.2 Global Severe Acute Respiratory Syndrome Treatment Annual Revenue by Company (2018-2023)
- 3.2.1 Global Severe Acute Respiratory Syndrome Treatment Revenue by Company (2018-2023)
- 3.2.2 Global Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Company (2018-2023)
- 3.3 Global Severe Acute Respiratory Syndrome Treatment Sale Price by Company
- 3.4 Key Manufacturers Severe Acute Respiratory Syndrome Treatment Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Severe Acute Respiratory Syndrome Treatment Product Location Distribution
  - 3.4.2 Players Severe Acute Respiratory Syndrome Treatment Products Offered
- 3.5 Market Concentration Rate Analysis
  - 3.5.1 Competition Landscape Analysis
  - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

# 4 WORLD HISTORIC REVIEW FOR SEVERE ACUTE RESPIRATORY SYNDROME TREATMENT BY GEOGRAPHIC REGION

4.1 World Historic Severe Acute Respiratory Syndrome Treatment Market Size by Geographic Region (2018-2023)



- 4.1.1 Global Severe Acute Respiratory Syndrome Treatment Annual Sales by Geographic Region (2018-2023)
- 4.1.2 Global Severe Acute Respiratory Syndrome Treatment Annual Revenue by Geographic Region (2018-2023)
- 4.2 World Historic Severe Acute Respiratory Syndrome Treatment Market Size by Country/Region (2018-2023)
- 4.2.1 Global Severe Acute Respiratory Syndrome Treatment Annual Sales by Country/Region (2018-2023)
- 4.2.2 Global Severe Acute Respiratory Syndrome Treatment Annual Revenue by Country/Region (2018-2023)
- 4.3 Americas Severe Acute Respiratory Syndrome Treatment Sales Growth
- 4.4 APAC Severe Acute Respiratory Syndrome Treatment Sales Growth
- 4.5 Europe Severe Acute Respiratory Syndrome Treatment Sales Growth
- 4.6 Middle East & Africa Severe Acute Respiratory Syndrome Treatment Sales Growth

#### **5 AMERICAS**

- 5.1 Americas Severe Acute Respiratory Syndrome Treatment Sales by Country
- 5.1.1 Americas Severe Acute Respiratory Syndrome Treatment Sales by Country (2018-2023)
- 5.1.2 Americas Severe Acute Respiratory Syndrome Treatment Revenue by Country (2018-2023)
- 5.2 Americas Severe Acute Respiratory Syndrome Treatment Sales by Type
- 5.3 Americas Severe Acute Respiratory Syndrome Treatment Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

#### 6 APAC

- 6.1 APAC Severe Acute Respiratory Syndrome Treatment Sales by Region
- 6.1.1 APAC Severe Acute Respiratory Syndrome Treatment Sales by Region (2018-2023)
- 6.1.2 APAC Severe Acute Respiratory Syndrome Treatment Revenue by Region (2018-2023)
- 6.2 APAC Severe Acute Respiratory Syndrome Treatment Sales by Type
- 6.3 APAC Severe Acute Respiratory Syndrome Treatment Sales by Application
- 6.4 China



- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

# **7 EUROPE**

- 7.1 Europe Severe Acute Respiratory Syndrome Treatment by Country
- 7.1.1 Europe Severe Acute Respiratory Syndrome Treatment Sales by Country (2018-2023)
- 7.1.2 Europe Severe Acute Respiratory Syndrome Treatment Revenue by Country (2018-2023)
- 7.2 Europe Severe Acute Respiratory Syndrome Treatment Sales by Type
- 7.3 Europe Severe Acute Respiratory Syndrome Treatment Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

# **8 MIDDLE EAST & AFRICA**

- 8.1 Middle East & Africa Severe Acute Respiratory Syndrome Treatment by Country
- 8.1.1 Middle East & Africa Severe Acute Respiratory Syndrome Treatment Sales by Country (2018-2023)
- 8.1.2 Middle East & Africa Severe Acute Respiratory Syndrome Treatment Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Severe Acute Respiratory Syndrome Treatment Sales by Type
- 8.3 Middle East & Africa Severe Acute Respiratory Syndrome Treatment Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

# 9 MARKET DRIVERS, CHALLENGES AND TRENDS



- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

### 10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Severe Acute Respiratory Syndrome Treatment
- 10.3 Manufacturing Process Analysis of Severe Acute Respiratory Syndrome Treatment
- 10.4 Industry Chain Structure of Severe Acute Respiratory Syndrome Treatment

# 11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
  - 11.1.1 Direct Channels
  - 11.1.2 Indirect Channels
- 11.2 Severe Acute Respiratory Syndrome Treatment Distributors
- 11.3 Severe Acute Respiratory Syndrome Treatment Customer

# 12 WORLD FORECAST REVIEW FOR SEVERE ACUTE RESPIRATORY SYNDROME TREATMENT BY GEOGRAPHIC REGION

- 12.1 Global Severe Acute Respiratory Syndrome Treatment Market Size Forecast by Region
- 12.1.1 Global Severe Acute Respiratory Syndrome Treatment Forecast by Region (2024-2029)
- 12.1.2 Global Severe Acute Respiratory Syndrome Treatment Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Severe Acute Respiratory Syndrome Treatment Forecast by Type
- 12.7 Global Severe Acute Respiratory Syndrome Treatment Forecast by Application

#### 13 KEY PLAYERS ANALYSIS



- 13.1 AstraZeneca plc
  - 13.1.1 AstraZeneca plc Company Information
- 13.1.2 AstraZeneca plc Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications
- 13.1.3 AstraZeneca plc Severe Acute Respiratory Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.1.4 AstraZeneca plc Main Business Overview
  - 13.1.5 AstraZeneca plc Latest Developments
- 13.2 Eli Lilly and Company
  - 13.2.1 Eli Lilly and Company Company Information
- 13.2.2 Eli Lilly and Company Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications
- 13.2.3 Eli Lilly and Company Severe Acute Respiratory Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.2.4 Eli Lilly and Company Main Business Overview
- 13.2.5 Eli Lilly and Company Latest Developments
- 13.3 F. Hoffmann-La Roche Ltd.
  - 13.3.1 F. Hoffmann-La Roche Ltd. Company Information
- 13.3.2 F. Hoffmann-La Roche Ltd. Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications
- 13.3.3 F. Hoffmann-La Roche Ltd. Severe Acute Respiratory Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.3.4 F. Hoffmann-La Roche Ltd. Main Business Overview
  - 13.3.5 F. Hoffmann-La Roche Ltd. Latest Developments
- 13.4 Gilead Sciences, Inc.
  - 13.4.1 Gilead Sciences, Inc. Company Information
- 13.4.2 Gilead Sciences, Inc. Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications
- 13.4.3 Gilead Sciences, Inc. Severe Acute Respiratory Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.4.4 Gilead Sciences, Inc. Main Business Overview
- 13.4.5 Gilead Sciences, Inc. Latest Developments
- 13.5 GSK
  - 13.5.1 GSK Company Information
- 13.5.2 GSK Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications
- 13.5.3 GSK Severe Acute Respiratory Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.5.4 GSK Main Business Overview



- 13.5.5 GSK Latest Developments
- 13.6 Merck
  - 13.6.1 Merck Company Information
- 13.6.2 Merck Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications
- 13.6.3 Merck Severe Acute Respiratory Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.6.4 Merck Main Business Overview
  - 13.6.5 Merck Latest Developments
- 13.7 Pfizer
  - 13.7.1 Pfizer Company Information
- 13.7.2 Pfizer Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications
- 13.7.3 Pfizer Severe Acute Respiratory Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.7.4 Pfizer Main Business Overview
  - 13.7.5 Pfizer Latest Developments
- 13.8 Regeneron Pharmaceuticals, Inc.
  - 13.8.1 Regeneron Pharmaceuticals, Inc. Company Information
- 13.8.2 Regeneron Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications
- 13.8.3 Regeneron Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.8.4 Regeneron Pharmaceuticals, Inc. Main Business Overview
  - 13.8.5 Regeneron Pharmaceuticals, Inc. Latest Developments
- 13.9 Swedish Orphan Biovitrum
  - 13.9.1 Swedish Orphan Biovitrum Company Information
- 13.9.2 Swedish Orphan Biovitrum Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications
- 13.9.3 Swedish Orphan Biovitrum Severe Acute Respiratory Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.9.4 Swedish Orphan Biovitrum Main Business Overview
  - 13.9.5 Swedish Orphan Biovitrum Latest Developments
- 13.10 CN Bio
  - 13.10.1 CN Bio Company Information
- 13.10.2 CN Bio Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications
- 13.10.3 CN Bio Severe Acute Respiratory Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)



- 13.10.4 CN Bio Main Business Overview
- 13.10.5 CN Bio Latest Developments
- 13.11 AbbVie
  - 13.11.1 AbbVie Company Information
- 13.11.2 AbbVie Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications
- 13.11.3 AbbVie Severe Acute Respiratory Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.11.4 AbbVie Main Business Overview
  - 13.11.5 AbbVie Latest Developments

### 14 RESEARCH FINDINGS AND CONCLUSION



# **List Of Tables**

### LIST OF TABLES

Table 1. Severe Acute Respiratory Syndrome Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Severe Acute Respiratory Syndrome Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Antibiotics

Table 4. Major Players of Antivirals

Table 5. Major Players of Corticosteroids

Table 6. Major Players of Monoclonal Antibodies

Table 7. Major Players of Others

Table 8. Global Severe Acute Respiratory Syndrome Treatment Sales by Type (2018-2023) & (K Units)

Table 9. Global Severe Acute Respiratory Syndrome Treatment Sales Market Share by Type (2018-2023)

Table 10. Global Severe Acute Respiratory Syndrome Treatment Revenue by Type (2018-2023) & (\$ million)

Table 11. Global Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Type (2018-2023)

Table 12. Global Severe Acute Respiratory Syndrome Treatment Sale Price by Type (2018-2023) & (US\$/Unit)

Table 13. Global Severe Acute Respiratory Syndrome Treatment Sales by Application (2018-2023) & (K Units)

Table 14. Global Severe Acute Respiratory Syndrome Treatment Sales Market Share by Application (2018-2023)

Table 15. Global Severe Acute Respiratory Syndrome Treatment Revenue by Application (2018-2023)

Table 16. Global Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Application (2018-2023)

Table 17. Global Severe Acute Respiratory Syndrome Treatment Sale Price by Application (2018-2023) & (US\$/Unit)

Table 18. Global Severe Acute Respiratory Syndrome Treatment Sales by Company (2018-2023) & (K Units)

Table 19. Global Severe Acute Respiratory Syndrome Treatment Sales Market Share by Company (2018-2023)

Table 20. Global Severe Acute Respiratory Syndrome Treatment Revenue by Company (2018-2023) (\$ Millions)



- Table 21. Global Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Company (2018-2023)
- Table 22. Global Severe Acute Respiratory Syndrome Treatment Sale Price by Company (2018-2023) & (US\$/Unit)
- Table 23. Key Manufacturers Severe Acute Respiratory Syndrome Treatment Producing Area Distribution and Sales Area
- Table 24. Players Severe Acute Respiratory Syndrome Treatment Products Offered
- Table 25. Severe Acute Respiratory Syndrome Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- Table 26. New Products and Potential Entrants
- Table 27. Mergers & Acquisitions, Expansion
- Table 28. Global Severe Acute Respiratory Syndrome Treatment Sales by Geographic Region (2018-2023) & (K Units)
- Table 29. Global Severe Acute Respiratory Syndrome Treatment Sales Market Share Geographic Region (2018-2023)
- Table 30. Global Severe Acute Respiratory Syndrome Treatment Revenue by Geographic Region (2018-2023) & (\$ millions)
- Table 31. Global Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Geographic Region (2018-2023)
- Table 32. Global Severe Acute Respiratory Syndrome Treatment Sales by Country/Region (2018-2023) & (K Units)
- Table 33. Global Severe Acute Respiratory Syndrome Treatment Sales Market Share by Country/Region (2018-2023)
- Table 34. Global Severe Acute Respiratory Syndrome Treatment Revenue by Country/Region (2018-2023) & (\$ millions)
- Table 35. Global Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Country/Region (2018-2023)
- Table 36. Americas Severe Acute Respiratory Syndrome Treatment Sales by Country (2018-2023) & (K Units)
- Table 37. Americas Severe Acute Respiratory Syndrome Treatment Sales Market Share by Country (2018-2023)
- Table 38. Americas Severe Acute Respiratory Syndrome Treatment Revenue by Country (2018-2023) & (\$ Millions)
- Table 39. Americas Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Country (2018-2023)
- Table 40. Americas Severe Acute Respiratory Syndrome Treatment Sales by Type (2018-2023) & (K Units)
- Table 41. Americas Severe Acute Respiratory Syndrome Treatment Sales by Application (2018-2023) & (K Units)



- Table 42. APAC Severe Acute Respiratory Syndrome Treatment Sales by Region (2018-2023) & (K Units)
- Table 43. APAC Severe Acute Respiratory Syndrome Treatment Sales Market Share by Region (2018-2023)
- Table 44. APAC Severe Acute Respiratory Syndrome Treatment Revenue by Region (2018-2023) & (\$ Millions)
- Table 45. APAC Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Region (2018-2023)
- Table 46. APAC Severe Acute Respiratory Syndrome Treatment Sales by Type (2018-2023) & (K Units)
- Table 47. APAC Severe Acute Respiratory Syndrome Treatment Sales by Application (2018-2023) & (K Units)
- Table 48. Europe Severe Acute Respiratory Syndrome Treatment Sales by Country (2018-2023) & (K Units)
- Table 49. Europe Severe Acute Respiratory Syndrome Treatment Sales Market Share by Country (2018-2023)
- Table 50. Europe Severe Acute Respiratory Syndrome Treatment Revenue by Country (2018-2023) & (\$ Millions)
- Table 51. Europe Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Country (2018-2023)
- Table 52. Europe Severe Acute Respiratory Syndrome Treatment Sales by Type (2018-2023) & (K Units)
- Table 53. Europe Severe Acute Respiratory Syndrome Treatment Sales by Application (2018-2023) & (K Units)
- Table 54. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Sales by Country (2018-2023) & (K Units)
- Table 55. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Sales Market Share by Country (2018-2023)
- Table 56. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Revenue by Country (2018-2023) & (\$ Millions)
- Table 57. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Country (2018-2023)
- Table 58. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Sales by Type (2018-2023) & (K Units)
- Table 59. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Sales by Application (2018-2023) & (K Units)
- Table 60. Key Market Drivers & Growth Opportunities of Severe Acute Respiratory Syndrome Treatment
- Table 61. Key Market Challenges & Risks of Severe Acute Respiratory Syndrome



### Treatment

- Table 62. Key Industry Trends of Severe Acute Respiratory Syndrome Treatment
- Table 63. Severe Acute Respiratory Syndrome Treatment Raw Material
- Table 64. Key Suppliers of Raw Materials
- Table 65. Severe Acute Respiratory Syndrome Treatment Distributors List
- Table 66. Severe Acute Respiratory Syndrome Treatment Customer List
- Table 67. Global Severe Acute Respiratory Syndrome Treatment Sales Forecast by Region (2024-2029) & (K Units)
- Table 68. Global Severe Acute Respiratory Syndrome Treatment Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 69. Americas Severe Acute Respiratory Syndrome Treatment Sales Forecast by Country (2024-2029) & (K Units)
- Table 70. Americas Severe Acute Respiratory Syndrome Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 71. APAC Severe Acute Respiratory Syndrome Treatment Sales Forecast by Region (2024-2029) & (K Units)
- Table 72. APAC Severe Acute Respiratory Syndrome Treatment Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 73. Europe Severe Acute Respiratory Syndrome Treatment Sales Forecast by Country (2024-2029) & (K Units)
- Table 74. Europe Severe Acute Respiratory Syndrome Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 75. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Sales Forecast by Country (2024-2029) & (K Units)
- Table 76. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 77. Global Severe Acute Respiratory Syndrome Treatment Sales Forecast by Type (2024-2029) & (K Units)
- Table 78. Global Severe Acute Respiratory Syndrome Treatment Revenue Forecast by Type (2024-2029) & (\$ Millions)
- Table 79. Global Severe Acute Respiratory Syndrome Treatment Sales Forecast by Application (2024-2029) & (K Units)
- Table 80. Global Severe Acute Respiratory Syndrome Treatment Revenue Forecast by Application (2024-2029) & (\$ Millions)
- Table 81. AstraZeneca plc Basic Information, Severe Acute Respiratory Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors
- Table 82. AstraZeneca plc Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications
- Table 83. AstraZeneca plc Severe Acute Respiratory Syndrome Treatment Sales (K



Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 84. AstraZeneca plc Main Business

Table 85. AstraZeneca plc Latest Developments

Table 86. Eli Lilly and Company Basic Information, Severe Acute Respiratory Syndrome

Treatment Manufacturing Base, Sales Area and Its Competitors

Table 87. Eli Lilly and Company Severe Acute Respiratory Syndrome Treatment

Product Portfolios and Specifications

Table 88. Eli Lilly and Company Severe Acute Respiratory Syndrome Treatment Sales

(K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 89. Eli Lilly and Company Main Business

Table 90. Eli Lilly and Company Latest Developments

Table 91. F. Hoffmann-La Roche Ltd. Basic Information, Severe Acute Respiratory

Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors

Table 92. F. Hoffmann-La Roche Ltd. Severe Acute Respiratory Syndrome Treatment

Product Portfolios and Specifications

Table 93. F. Hoffmann-La Roche Ltd. Severe Acute Respiratory Syndrome Treatment

Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 94. F. Hoffmann-La Roche Ltd. Main Business

Table 95. F. Hoffmann-La Roche Ltd. Latest Developments

Table 96. Gilead Sciences, Inc. Basic Information, Severe Acute Respiratory Syndrome

Treatment Manufacturing Base, Sales Area and Its Competitors

Table 97. Gilead Sciences, Inc. Severe Acute Respiratory Syndrome Treatment Product

Portfolios and Specifications

Table 98. Gilead Sciences, Inc. Severe Acute Respiratory Syndrome Treatment Sales

(K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 99. Gilead Sciences, Inc. Main Business

Table 100. Gilead Sciences, Inc. Latest Developments

Table 101. GSK Basic Information, Severe Acute Respiratory Syndrome Treatment

Manufacturing Base, Sales Area and Its Competitors

Table 102. GSK Severe Acute Respiratory Syndrome Treatment Product Portfolios and

Specifications

Table 103. GSK Severe Acute Respiratory Syndrome Treatment Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 104. GSK Main Business

Table 105. GSK Latest Developments

Table 106. Merck Basic Information, Severe Acute Respiratory Syndrome Treatment

Manufacturing Base, Sales Area and Its Competitors

Table 107. Merck Severe Acute Respiratory Syndrome Treatment Product Portfolios

and Specifications



Table 108. Merck Severe Acute Respiratory Syndrome Treatment Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 109. Merck Main Business

Table 110. Merck Latest Developments

Table 111. Pfizer Basic Information, Severe Acute Respiratory Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors

Table 112. Pfizer Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications

Table 113. Pfizer Severe Acute Respiratory Syndrome Treatment Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 114. Pfizer Main Business

Table 115. Pfizer Latest Developments

Table 116. Regeneron Pharmaceuticals, Inc. Basic Information, Severe Acute

Respiratory Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors

Table 117. Regeneron Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome

Treatment Product Portfolios and Specifications

Table 118. Regeneron Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome Treatment Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 119. Regeneron Pharmaceuticals, Inc. Main Business

Table 120. Regeneron Pharmaceuticals, Inc. Latest Developments

Table 121. Swedish Orphan Biovitrum Basic Information, Severe Acute Respiratory

Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors

Table 122. Swedish Orphan Biovitrum Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications

Table 123. Swedish Orphan Biovitrum Severe Acute Respiratory Syndrome Treatment

Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 124. Swedish Orphan Biovitrum Main Business

Table 125. Swedish Orphan Biovitrum Latest Developments

Table 126. CN Bio Basic Information, Severe Acute Respiratory Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors

Table 127. CN Bio Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications

Table 128. CN Bio Severe Acute Respiratory Syndrome Treatment Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 129. CN Bio Main Business

Table 130. CN Bio Latest Developments

Table 131. AbbVie Basic Information, Severe Acute Respiratory Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors



Table 132. AbbVie Severe Acute Respiratory Syndrome Treatment Product Portfolios and Specifications

Table 133. AbbVie Severe Acute Respiratory Syndrome Treatment Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 134. AbbVie Main Business

Table 135. AbbVie Latest Developments



# **List Of Figures**

### **LIST OF FIGURES**

- Figure 1. Picture of Severe Acute Respiratory Syndrome Treatment
- Figure 2. Severe Acute Respiratory Syndrome Treatment Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Severe Acute Respiratory Syndrome Treatment Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Severe Acute Respiratory Syndrome Treatment Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Severe Acute Respiratory Syndrome Treatment Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Antibiotics
- Figure 10. Product Picture of Antivirals
- Figure 11. Product Picture of Corticosteroids
- Figure 12. Product Picture of Monoclonal Antibodies
- Figure 13. Product Picture of Others
- Figure 14. Global Severe Acute Respiratory Syndrome Treatment Sales Market Share by Type in 2022
- Figure 15. Global Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Type (2018-2023)
- Figure 16. Severe Acute Respiratory Syndrome Treatment Consumed in Hospital
- Figure 17. Global Severe Acute Respiratory Syndrome Treatment Market: Hospital (2018-2023) & (K Units)
- Figure 18. Severe Acute Respiratory Syndrome Treatment Consumed in Retail pharmacies
- Figure 19. Global Severe Acute Respiratory Syndrome Treatment Market: Retail pharmacies (2018-2023) & (K Units)
- Figure 20. Severe Acute Respiratory Syndrome Treatment Consumed in Others
- Figure 21. Global Severe Acute Respiratory Syndrome Treatment Market: Others (2018-2023) & (K Units)
- Figure 22. Global Severe Acute Respiratory Syndrome Treatment Sales Market Share by Application (2022)
- Figure 23. Global Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Application in 2022
- Figure 24. Severe Acute Respiratory Syndrome Treatment Sales Market by Company in



2022 (K Units)

Figure 25. Global Severe Acute Respiratory Syndrome Treatment Sales Market Share by Company in 2022

Figure 26. Severe Acute Respiratory Syndrome Treatment Revenue Market by Company in 2022 (\$ Million)

Figure 27. Global Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Company in 2022

Figure 28. Global Severe Acute Respiratory Syndrome Treatment Sales Market Share by Geographic Region (2018-2023)

Figure 29. Global Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Geographic Region in 2022

Figure 30. Americas Severe Acute Respiratory Syndrome Treatment Sales 2018-2023 (K Units)

Figure 31. Americas Severe Acute Respiratory Syndrome Treatment Revenue 2018-2023 (\$ Millions)

Figure 32. APAC Severe Acute Respiratory Syndrome Treatment Sales 2018-2023 (K Units)

Figure 33. APAC Severe Acute Respiratory Syndrome Treatment Revenue 2018-2023 (\$ Millions)

Figure 34. Europe Severe Acute Respiratory Syndrome Treatment Sales 2018-2023 (K Units)

Figure 35. Europe Severe Acute Respiratory Syndrome Treatment Revenue 2018-2023 (\$ Millions)

Figure 36. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Sales 2018-2023 (K Units)

Figure 37. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Revenue 2018-2023 (\$ Millions)

Figure 38. Americas Severe Acute Respiratory Syndrome Treatment Sales Market Share by Country in 2022

Figure 39. Americas Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Country in 2022

Figure 40. Americas Severe Acute Respiratory Syndrome Treatment Sales Market Share by Type (2018-2023)

Figure 41. Americas Severe Acute Respiratory Syndrome Treatment Sales Market Share by Application (2018-2023)

Figure 42. United States Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 43. Canada Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)



Figure 44. Mexico Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 45. Brazil Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 46. APAC Severe Acute Respiratory Syndrome Treatment Sales Market Share by Region in 2022

Figure 47. APAC Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Regions in 2022

Figure 48. APAC Severe Acute Respiratory Syndrome Treatment Sales Market Share by Type (2018-2023)

Figure 49. APAC Severe Acute Respiratory Syndrome Treatment Sales Market Share by Application (2018-2023)

Figure 50. China Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 51. Japan Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 52. South Korea Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Southeast Asia Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 54. India Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 55. Australia Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 56. China Taiwan Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 57. Europe Severe Acute Respiratory Syndrome Treatment Sales Market Share by Country in 2022

Figure 58. Europe Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Country in 2022

Figure 59. Europe Severe Acute Respiratory Syndrome Treatment Sales Market Share by Type (2018-2023)

Figure 60. Europe Severe Acute Respiratory Syndrome Treatment Sales Market Share by Application (2018-2023)

Figure 61. Germany Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 62. France Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 63. UK Severe Acute Respiratory Syndrome Treatment Revenue Growth



2018-2023 (\$ Millions)

Figure 64. Italy Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 65. Russia Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 66. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Sales Market Share by Country in 2022

Figure 67. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Revenue Market Share by Country in 2022

Figure 68. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Sales Market Share by Type (2018-2023)

Figure 69. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Sales Market Share by Application (2018-2023)

Figure 70. Egypt Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 71. South Africa Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 72. Israel Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 73. Turkey Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 74. GCC Country Severe Acute Respiratory Syndrome Treatment Revenue Growth 2018-2023 (\$ Millions)

Figure 75. Manufacturing Cost Structure Analysis of Severe Acute Respiratory Syndrome Treatment in 2022

Figure 76. Manufacturing Process Analysis of Severe Acute Respiratory Syndrome Treatment

Figure 77. Industry Chain Structure of Severe Acute Respiratory Syndrome Treatment Figure 78. Channels of Distribution

Figure 79. Global Severe Acute Respiratory Syndrome Treatment Sales Market Forecast by Region (2024-2029)

Figure 80. Global Severe Acute Respiratory Syndrome Treatment Revenue Market Share Forecast by Region (2024-2029)

Figure 81. Global Severe Acute Respiratory Syndrome Treatment Sales Market Share Forecast by Type (2024-2029)

Figure 82. Global Severe Acute Respiratory Syndrome Treatment Revenue Market Share Forecast by Type (2024-2029)

Figure 83. Global Severe Acute Respiratory Syndrome Treatment Sales Market Share Forecast by Application (2024-2029)



Figure 84. Global Severe Acute Respiratory Syndrome Treatment Revenue Market Share Forecast by Application (2024-2029)



# I would like to order

Product name: Global Severe Acute Respiratory Syndrome Treatment Market Growth 2023-2029

Product link: https://marketpublishers.com/r/GBA03A64FBC8EN.html

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/GBA03A64FBC8EN.html">https://marketpublishers.com/r/GBA03A64FBC8EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970